Cerecor Inc. Company Profile
Cerecor Inc., a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. It develops CERC-301 that is in Phase II development stage for the adjunctive treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development stage for the adjunctive treatment of MDD, as well as to treat substance use disorders; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.